Back to top
more

Halozyme Therapeutics (HALO)

(Delayed Data from NSDQ)

$38.57 USD

38.57
547,082

+0.11 (0.29%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $38.55 -0.02 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Why the Earnings Surprise Streak Could Continue for Halozyme Therapeutics (HALO)

by Zacks Equity Research

Halozyme Therapeutics (HALO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Glaxo's (GSK) Long-Acting Drug NDA Gets Priority Tag for PrEP

by Zacks Equity Research

Glaxo's (GSK) HIV subsidiary, ViiV Healthcare gets FDA's priority review for a new drug application for long-acting cabotegravir regimen. ViiV Healthcare signs a deal for developing ultra long-acting HIV treatment.

Halozyme Therapeutics (HALO) Up 4.2% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Halozyme (HALO) Beats on Q2 Earnings, Raises 2021 Guidance

by Zacks Equity Research

Halozyme (HALO) second-quarter earnings and sales beat estimates. The company raises 2021 guidance. Stock up.

Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 53.49% and 30.79%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

5 Drug/Biotech Stocks Set to Outpace Q2 Earnings Estimates

by Kinjel Shah

Let us take a look at some drug/biotech stocks - FSTX, HALO, KNTE, RUBY and SPRB - that are poised to beat on second-quarter earnings.

Why Halozyme (HALO) Might Surprise This Earnings Season

by Zacks Equity Research

Halozyme (HALO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Halozyme Therapeutics (HALO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Halozyme Therapeutics (HALO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

TFF Pharmaceuticals (TFFP) Completes Enrollment in Phase I Study

by Zacks Equity Research

TFF Pharmaceuticals (TFFP) completes enrollment in the phase I study on tacrolimus inhalation powder and announces positive preliminary data.

Halozyme (HALO) Inks Collaboration Deal With Glaxo's HIV Unit

by Zacks Equity Research

Halozyme (HALO) and Glaxo's HIV company, ViiV Healthcare sign a collaboration agreement, which gives the latter exclusive right to Halozyme's ENHANZE technology to develop therapies targeting HIV

Glaxo (GSK)/Vir Affirm COVID-19 Drug Cuts Hospitalization/Death

by Zacks Equity Research

Glaxo (GSK)/Vir Biotech's new data confirms that COVID-19 treatment, sotrovimab can cut hospitalization and risk of death. ViiV Healthcare inks deal with Halozyme to use its ENHANZE technology to make better HIV medicines.

Why Is Halozyme Therapeutics (HALO) Down 7.5% Since Last Earnings Report?

by Zacks Equity Research

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Halozyme (HALO) Stock Down Despite Q1 Earnings & Sales Beat

by Zacks Equity Research

Halozyme (HALO) first-quarter earnings and sales beat estimates. The company retains 2021 guidance.

Halozyme Therapeutics (HALO) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 19.35% and 5.19%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Halozyme Therapeutics (HALO) Down 19.3% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Halozyme (HALO) Q4 Earnings Miss, 2021 View Weak, Stock Falls

by Zacks Equity Research

Halozyme (HALO) reports lower-than-expected fourth-quarter earnings. However, revenues beat estimates. The company's outlook for 2021 is below market expectations.

Kinjel Shah headshot

Drug/Biotech Stock Q4 Earnings on Feb 23: JAZZ, ARNA & More

by Kinjel Shah

Let us take a look at five small biotech companies, JAZZ, ARNA, HALO, EPZM, ESPR, which are gearing up for their earnings release.

UnitedHealth (UNH) Q4 Earnings Top Estimates, Revenues up Y/Y

by Zacks Equity Research

UnitedHealth's (UNH) fourth-quarter results benefit from higher revenues and return of healthcare utilization to normalcy level, partly offset by higher costs.

Precision BioSciences' (DTIL) New Lymphoma Drug IND Gets FDA Nod

by Zacks Equity Research

The FDA accepts Precision BioSciences' (DTIL) regulatory application to initiate a clinical study on its next-generation CD19 product candidate, PBCAR19B.

J&J's (JNJ) Darzalex Faspro Gets FDA Nod for Amyloidosis

by Zacks Equity Research

J&J (JNJ) gets accelerated approval for a new indication of Darzalex Faspro in combination with bortezomib, cyclophosphamide and dexamethasone for treating amyloidosis patients.

Novartis' (NVS) Ligelizumab Gets Breakthrough Therapy Status

by Zacks Equity Research

Novartis (NVS) gets Breakthrough Therapy designation by the FDA for ligelizumab for the treatment of chronic spontaneous urticaria.

Lexicon (LXRX) Soars on FDA Permission for Sotagliflozin NDA

by Zacks Equity Research

Lexicon (LXRX) announces that data from two late-stage studies on its type II diabetes candidate, sotagliflozin, can support a regulatory approval application.

Acorda (ACOR) Soars on Sale of Manufacturing Unit for Inbrija

by Zacks Equity Research

Acorda (ACOR) inks an agreement to sell its Inbrija manufacturing operations in Chelsea for $80 million to Catalent. The company also announces a corporate restructuring plan to save costs. Shares up.

Marinus (MRNS) Gets Positive FDA Response for Ganaxolone Study

by Zacks Equity Research

Marinus (MRNS) gets positive FDA response for phase III Marigold study on oral ganaxolone in children and young adults with CDKL5 deficiency disorder that appears sufficient to support the NDA filing.